Eupraxia Reports 52-Week Durability Data from Highest Dose Cohort of EP-104GI in RESOLVE Trial
EPRX sits 61% above its 52-week low of $5.25.
Summary
Eupraxia reported 52-week data from the highest dose cohort of EP-104GI in its RESOLVE trial, showing durable clinical remission and a clean safety profile. The results support the potential for annual dosing in eosinophilic esophagitis.
Key Events · Product Development and Regulatory · EPRX
-
52-Week Durability Data from Cohort 9
66% of patients (2 of 3) in the highest dose cohort (20 x 8 mg) maintained clinical remission at 52 weeks, with a mean SDI reduction of 3.0 at both 36 and 52 weeks.
-
Histologic Improvement in Cohort 8b
Cohort 8b (20 x 6 mg) showed EoEHSS Stage -0.26 and Grade -0.27 at 36 weeks, indicating meaningful reduction in inflammation and fibrosis.
-
Overall Remission Rate Across Cohorts 5-9
64% (9/14) of patients remained in clinical remission 52 weeks after a single administration of EP-104GI.
-
Clean Safety Profile
No treatment-related serious adverse events, no oropharyngeal candidiasis, and no adrenal insufficiency or glucose derangement reported to date.
Analysis · EPRX · Life Sciences
Eupraxia disclosed 52-week data from the highest dose cohort of its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis. The data show durable symptom responses and clinical remission rates, with 64% of patients across cohorts 5-9 maintaining remission at 52 weeks after a single administration. No treatment-related serious adverse events or oropharyngeal candidiasis were observed. This strengthens the case for an annual dosing regimen and supports the ongoing Phase 2b trial, with interim data expected in December 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EPRX was trading at $8.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $547.4M. The 52-week trading range was $5.25 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.